Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Giulia Marvaso, et al. on X:
“In patients with metachronous oligorecurrent hormone-sensitive Prostate Cancer, adding 6 months of ADT to SBRT significantly improved clinical progression-free survival compared to SBRT alone!
- Phase 2, randomized trial.
- 105 patients, single-center (European Institute of Oncology, Milan).
- SBRT (30 Gy/3 fx) ± 6 months ADT.”
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.
Authors: Giulia Marvaso, et al.
